http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20030074640-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2001-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20030074640-A |
| titleOfInvention | Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates |
| abstract | The present invention relates to prognostic methods useful in the medical field, in particular for cancer chemotherapy. It is an object of the present invention to assess HER2-neu and / or EGFR expression levels in fixed or immobilized paraffin-embedded tissues, and by examining the amount of HER2-neu and / or EGFR mRNA in tumor cells of a patient. It is to provide a method of prognosing the expected susceptibility of a patient's tumor to treatment with tyrosine kinase targeted chemotherapy, and comparing it to a predetermined threshold expression level for the gene. More specifically, the present invention provides a method comprising using these oligonucleotide primer pairs EGFR and HER2-neu , and identifying these levels of EGFR and HER2-neu mRNA, respectively. |
| priorityDate | 2000-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 295.